Short Interest in The Oncology Institute, Inc. (NASDAQ:TOI) Expands By 86.8%

The Oncology Institute, Inc. (NASDAQ:TOI) was the recipient of a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 324,100 shares, a growth of 86.8% from the December 31st total of 173,500 shares. Currently, 0.9% of the shares of the company are sold short. Based on an average daily volume of 1,740,000 shares, the days-to-cover ratio is currently 0.2 days.

Oncology Institute Price Performance

Shares of TOI stock traded up $0.05 during mid-day trading on Wednesday, reaching $0.84. The company’s stock had a trading volume of 506,698 shares, compared to its average volume of 932,877. Oncology Institute has a 1-year low of $0.13 and a 1-year high of $2.23. The company has a debt-to-equity ratio of 5.91, a quick ratio of 2.27 and a current ratio of 2.49. The company has a market cap of $63.47 million, a P/E ratio of -1.08 and a beta of 0.13. The firm’s 50-day moving average is $0.31 and its two-hundred day moving average is $0.35.

Insiders Place Their Bets

In other Oncology Institute news, Director Brad Hively bought 250,000 shares of the stock in a transaction on Tuesday, November 26th. The shares were purchased at an average price of $0.17 per share, with a total value of $42,500.00. Following the acquisition, the director now directly owns 616,753 shares of the company’s stock, valued at $104,848.01. This represents a 68.17 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 9.50% of the company’s stock.

Institutional Investors Weigh In On Oncology Institute

A hedge fund recently raised its stake in Oncology Institute stock. HighTower Advisors LLC grew its holdings in The Oncology Institute, Inc. (NASDAQ:TOI) by 190.8% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 81,362 shares of the company’s stock after buying an additional 53,382 shares during the quarter. HighTower Advisors LLC owned approximately 0.11% of Oncology Institute worth $27,000 at the end of the most recent reporting period. 36.86% of the stock is currently owned by hedge funds and other institutional investors.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.